Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,291–1,300 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1291
- Medicine slug
- raloxifene
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 23
- Source count
- 23
- Agreement rate
- 1
- Recorded readings
27.7 hours
- Numeric value
- 27.7
- Unit
- hours
- Source records
- 23
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 23 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c25553-1546-451d-8069-c0f484c47741 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fef5bfd-a786-4442-b09b-f3b81812cdac (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:804e873e-f48b-4c25-ad7b-41d44f61bdde (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b6cbe0-c1f4-4678-b852-f629a7f6a1b5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3568ed3c-6afd-4872-a861-93a7873bec9c (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a46bcc4f-f63d-4200-836d-a653a3c616db (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd63a06-5bc5-4c50-9b85-b09c89100b80 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53a2db10-4af8-4032-b598-b7c7a0969801 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b94ecf5-d870-4132-b455-d5ee5c9dce56 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c05521f8-95d2-44b8-8433-eba539c0f84c (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8152e68b-61a8-4897-8e03-900135b1dbd5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7eb934-aa60-51e1-e053-2a91aa0a3914 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a951ee-2ffc-4c60-b681-0f80285153e1 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3ef791-ac90-4f66-8da6-95b31e4c3eb6 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f24455c-34dc-4e07-bcd3-24326b9cc377 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a22ae27-1c55-487b-8e93-8ef1cec87065 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2967d3c-238c-40cf-b3d8-89482a502928 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6be5b1d-757d-4bab-ad6a-c421960a104d (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e4bfee5-fefc-4115-9bdb-222eccefca83 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f7d1f81-374f-4ad5-aea0-2f97abbe1dbf (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0db29f5-28da-4165-94f8-24727b6b71e5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3798c70b-a4b0-4811-9788-e4c9cff47ebe (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Raloxifene and its glucuronide conjugates are interconverted by reversible systemic metabolism and enterohepatic cycling, thereby prolonging its plasma elimination half-life to 27.7 hours after oral dosing.
Projected row 1292
- Medicine slug
- raloxifene
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 23
- Source count
- 23
- Agreement rate
- 0.782609
- Recorded readings
2348 L/kg
- Numeric value
- 2,348
- Unit
- L/kg
- Source records
- 18
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 18 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5c25553-1546-451d-8069-c0f484c47741 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fef5bfd-a786-4442-b09b-f3b81812cdac (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:804e873e-f48b-4c25-ad7b-41d44f61bdde (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene hydrochloride, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8b6cbe0-c1f4-4678-b852-f629a7f6a1b5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene hydrochloride, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3568ed3c-6afd-4872-a861-93a7873bec9c (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fd63a06-5bc5-4c50-9b85-b09c89100b80 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53a2db10-4af8-4032-b598-b7c7a0969801 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b94ecf5-d870-4132-b455-d5ee5c9dce56 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c05521f8-95d2-44b8-8433-eba539c0f84c (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8152e68b-61a8-4897-8e03-900135b1dbd5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f7eb934-aa60-51e1-e053-2a91aa0a3914 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad3ef791-ac90-4f66-8da6-95b31e4c3eb6 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f24455c-34dc-4e07-bcd3-24326b9cc377 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a22ae27-1c55-487b-8e93-8ef1cec87065 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene hydrochloride, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2967d3c-238c-40cf-b3d8-89482a502928 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6be5b1d-757d-4bab-ad6a-c421960a104d (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f7d1f81-374f-4ad5-aea0-2f97abbe1dbf (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene hydrochloride, the apparent volume of distribution is 2348 L/kg and is not dose dependent.
2,348 L/kg
- Numeric value
- 2,348
- Unit
- L/kg
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a46bcc4f-f63d-4200-836d-a653a3c616db (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2,348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22a951ee-2ffc-4c60-b681-0f80285153e1 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2,348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e4bfee5-fefc-4115-9bdb-222eccefca83 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2,348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0db29f5-28da-4165-94f8-24727b6b71e5 (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 to 150 mg of raloxifene HCl, the apparent volume of distribution is 2,348 L/kg and is not dose dependent.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3798c70b-a4b0-4811-9788-e4c9cff47ebe (opens source in a new tab)
Raloxifene label
Version not recorded · Effective date not recorded
Distribution — Following oral administration of single doses ranging from 30 mg to 150 mg of raloxifene hydrochloride, the apparent volume of distribution is 2,348 L/kg and is not dose dependent.
Projected row 1293
- Medicine slug
- raltegravir
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:090aa265-9fc8-4aea-81fe-ce052c3f38df (opens source in a new tab)
Raltegravir label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption Raltegravir, given 400 mg twice daily, is absorbed with a T max of approximately 3 hours postdose in the fasted state in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccc6f2f9-696f-4ef9-bb4c-e0198d957b0b (opens source in a new tab)
Raltegravir label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption Raltegravir, given 400 mg twice daily, is absorbed with a T max of approximately 3 hours postdose in the fasted state in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e659505-c902-4906-9461-1cc83e2236d2 (opens source in a new tab)
Raltegravir label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption Raltegravir, given 400 mg twice daily, is absorbed with a T max of approximately 3 hours postdose in the fasted state in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46ef8e2e-ae63-6a3c-e054-00144ff8d46c (opens source in a new tab)
Raltegravir label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption Raltegravir (film-coated tablet) is absorbed with a T max of approximately 3 hours postdose in the fasted state.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:89a5ec53-d956-4329-8004-0f40f51c88a3 (opens source in a new tab)
Raltegravir label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Adults Absorption Raltegravir, given 400 mg twice daily, is absorbed with a T max of approximately 3 hours postdose in the fasted state in healthy subjects.
Projected row 1294
- Medicine slug
- ramelteon
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
1.8%
- Numeric value
- 1.8
- Unit
- %
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2fc3b7-4600-c14e-e053-6394a90a2586 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ca849d3-f0ba-45b5-9aec-f4b7ea105fac (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fc0db5-c68f-5af9-e053-2a95a90a5110 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b24572-f601-b092-e063-6394a90afa53 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d22e6ae-2373-4a2f-8dda-d223230c6010 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1b48a-05c0-4058-8ccd-1971098b8ce1 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:094d5aa0-aa29-4898-928a-fe0d283a5271 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed37ac7c-ab7e-57b3-e053-2995a90a5b90 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b336438f-7951-d3b7-e053-2995a90a4d69 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c14d79c-ece1-40c7-b725-eeb85d6f347a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44be28b2-f079-40ce-b86d-8b60eda1a7c0 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:782503c6-a82f-4933-aa04-399123e9f5a9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15c8612-4065-4078-bff9-f2ffc1319654 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d1ac8d-5131-4eed-e063-6294a90a402e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a57843-81cb-474d-8e90-e04bbe93216a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6ad234-69ae-4e33-824d-cff5d1500a86 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c1ba52a-8e7a-844a-6c48-d1c9bf9fff0e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0cc378-4bc5-425c-8f41-43eb734c24d9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfc4c5-07d1-4dd7-a9ca-a94203b2e16d (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:229403c5-de9c-dc61-e063-6394a90a2a70 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8213998f-9a14-4ebb-a87a-4f33416dfb21 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e55aea01-80e6-60ae-e053-2995a90a9ca2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7545c79a-93ea-4f73-beb5-cac46b2ed7e9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd169dd8-70a0-b6b4-e053-6394a90a3a6f (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a3cf917-3569-4fc1-8b81-ffecfd2de005 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00f0fbda-eb62-4f79-ae9c-286b31eca733 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:208dbac2-2634-4aff-8e2c-e5ecb47145e2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5db0e3ff-fefb-4c54-b9f9-b555e482e147 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57536bd9-7dfa-4be5-854a-95fea43d54bc (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon tablet is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4239d09-2cb3-4e7d-b035-995ddcf386df (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c52e03-4c2e-4774-9397-f1f0ee99b320 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c25cf94-f30e-4940-9f8b-3cb34258ba04 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af1db3bf-1c7c-441e-8497-7c35f45fb00e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86296f99-efef-4cbb-84cb-097b2edcfe9c (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de82310-70e8-47b9-b1fc-6c6848b99455 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bccc4f11-6081-49a1-9abd-2f4c2d69b380 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89dae05-6c39-4072-b8ee-c4c35b46f7d4 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b9b6076-180e-428b-b50a-5ab68ff65919 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1706aa1-9332-4faf-8d0c-88edd00b15e3 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5245f9ee-b4ca-24b6-e063-6394a90a0b1b (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Although the total absorption of ramelteon is at least 84%, the absolute oral bioavailability is only 1.8% due to extensive first-pass metabolism.
Projected row 1295
- Medicine slug
- ramelteon
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
2.6 hours
- Numeric value
- 2.6
- Unit
- hours
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2fc3b7-4600-c14e-e053-6394a90a2586 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ca849d3-f0ba-45b5-9aec-f4b7ea105fac (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fc0db5-c68f-5af9-e053-2a95a90a5110 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b24572-f601-b092-e063-6394a90afa53 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d22e6ae-2373-4a2f-8dda-d223230c6010 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1b48a-05c0-4058-8ccd-1971098b8ce1 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:094d5aa0-aa29-4898-928a-fe0d283a5271 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed37ac7c-ab7e-57b3-e053-2995a90a5b90 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b336438f-7951-d3b7-e053-2995a90a4d69 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c14d79c-ece1-40c7-b725-eeb85d6f347a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44be28b2-f079-40ce-b86d-8b60eda1a7c0 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:782503c6-a82f-4933-aa04-399123e9f5a9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15c8612-4065-4078-bff9-f2ffc1319654 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d1ac8d-5131-4eed-e063-6294a90a402e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a57843-81cb-474d-8e90-e04bbe93216a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6ad234-69ae-4e33-824d-cff5d1500a86 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c1ba52a-8e7a-844a-6c48-d1c9bf9fff0e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon table ts does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0cc378-4bc5-425c-8f41-43eb734c24d9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfc4c5-07d1-4dd7-a9ca-a94203b2e16d (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:229403c5-de9c-dc61-e063-6394a90a2a70 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon tabletsdoes not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8213998f-9a14-4ebb-a87a-4f33416dfb21 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e55aea01-80e6-60ae-e053-2995a90a9ca2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7545c79a-93ea-4f73-beb5-cac46b2ed7e9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd169dd8-70a0-b6b4-e053-6394a90a3a6f (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a3cf917-3569-4fc1-8b81-ffecfd2de005 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00f0fbda-eb62-4f79-ae9c-286b31eca733 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:208dbac2-2634-4aff-8e2c-e5ecb47145e2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5db0e3ff-fefb-4c54-b9f9-b555e482e147 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57536bd9-7dfa-4be5-854a-95fea43d54bc (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon tablets (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4239d09-2cb3-4e7d-b035-995ddcf386df (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c52e03-4c2e-4774-9397-f1f0ee99b320 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c25cf94-f30e-4940-9f8b-3cb34258ba04 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af1db3bf-1c7c-441e-8497-7c35f45fb00e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86296f99-efef-4cbb-84cb-097b2edcfe9c (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de82310-70e8-47b9-b1fc-6c6848b99455 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ROZEREM does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bccc4f11-6081-49a1-9abd-2f4c2d69b380 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one hours to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89dae05-6c39-4072-b8ee-c4c35b46f7d4 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b9b6076-180e-428b-b50a-5ab68ff65919 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1706aa1-9332-4faf-8d0c-88edd00b15e3 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with Ramelteon Tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5245f9ee-b4ca-24b6-e063-6394a90a0b1b (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Repeated once daily dosing with ramelteon tablets does not result in significant accumulation owing to the short elimination half-life of ramelteon (on average, approximately one to 2.6 hours).
Projected row 1296
- Medicine slug
- ramelteon
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
82%
- Numeric value
- 82
- Unit
- %
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2fc3b7-4600-c14e-e053-6394a90a2586 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ca849d3-f0ba-45b5-9aec-f4b7ea105fac (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fc0db5-c68f-5af9-e053-2a95a90a5110 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b24572-f601-b092-e063-6394a90afa53 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d22e6ae-2373-4a2f-8dda-d223230c6010 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1b48a-05c0-4058-8ccd-1971098b8ce1 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:094d5aa0-aa29-4898-928a-fe0d283a5271 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed37ac7c-ab7e-57b3-e053-2995a90a5b90 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b336438f-7951-d3b7-e053-2995a90a4d69 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c14d79c-ece1-40c7-b725-eeb85d6f347a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44be28b2-f079-40ce-b86d-8b60eda1a7c0 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:782503c6-a82f-4933-aa04-399123e9f5a9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15c8612-4065-4078-bff9-f2ffc1319654 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d1ac8d-5131-4eed-e063-6294a90a402e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a57843-81cb-474d-8e90-e04bbe93216a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6ad234-69ae-4e33-824d-cff5d1500a86 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c1ba52a-8e7a-844a-6c48-d1c9bf9fff0e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0cc378-4bc5-425c-8f41-43eb734c24d9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfc4c5-07d1-4dd7-a9ca-a94203b2e16d (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:229403c5-de9c-dc61-e063-6394a90a2a70 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8213998f-9a14-4ebb-a87a-4f33416dfb21 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e55aea01-80e6-60ae-e053-2995a90a9ca2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7545c79a-93ea-4f73-beb5-cac46b2ed7e9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd169dd8-70a0-b6b4-e053-6394a90a3a6f (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a3cf917-3569-4fc1-8b81-ffecfd2de005 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00f0fbda-eb62-4f79-ae9c-286b31eca733 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:208dbac2-2634-4aff-8e2c-e5ecb47145e2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5db0e3ff-fefb-4c54-b9f9-b555e482e147 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57536bd9-7dfa-4be5-854a-95fea43d54bc (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon tablets is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4239d09-2cb3-4e7d-b035-995ddcf386df (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c52e03-4c2e-4774-9397-f1f0ee99b320 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c25cf94-f30e-4940-9f8b-3cb34258ba04 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af1db3bf-1c7c-441e-8497-7c35f45fb00e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86296f99-efef-4cbb-84cb-097b2edcfe9c (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de82310-70e8-47b9-b1fc-6c6848b99455 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bccc4f11-6081-49a1-9abd-2f4c2d69b380 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89dae05-6c39-4072-b8ee-c4c35b46f7d4 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b9b6076-180e-428b-b50a-5ab68ff65919 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1706aa1-9332-4faf-8d0c-88edd00b15e3 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5245f9ee-b4ca-24b6-e063-6394a90a0b1b (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Distribution In vitro protein binding of ramelteon is approximately 82% in human serum, independent of concentration.
Projected row 1297
- Medicine slug
- ramelteon
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
0.75 hour
- Numeric value
- 0.75
- Unit
- hours
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2fc3b7-4600-c14e-e053-6394a90a2586 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ca849d3-f0ba-45b5-9aec-f4b7ea105fac (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fc0db5-c68f-5af9-e053-2a95a90a5110 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b24572-f601-b092-e063-6394a90afa53 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d22e6ae-2373-4a2f-8dda-d223230c6010 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1b48a-05c0-4058-8ccd-1971098b8ce1 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:094d5aa0-aa29-4898-928a-fe0d283a5271 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed37ac7c-ab7e-57b3-e053-2995a90a5b90 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b336438f-7951-d3b7-e053-2995a90a4d69 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c14d79c-ece1-40c7-b725-eeb85d6f347a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44be28b2-f079-40ce-b86d-8b60eda1a7c0 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:782503c6-a82f-4933-aa04-399123e9f5a9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15c8612-4065-4078-bff9-f2ffc1319654 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d1ac8d-5131-4eed-e063-6294a90a402e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a57843-81cb-474d-8e90-e04bbe93216a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6ad234-69ae-4e33-824d-cff5d1500a86 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c1ba52a-8e7a-844a-6c48-d1c9bf9fff0e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0cc378-4bc5-425c-8f41-43eb734c24d9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfc4c5-07d1-4dd7-a9ca-a94203b2e16d (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:229403c5-de9c-dc61-e063-6394a90a2a70 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8213998f-9a14-4ebb-a87a-4f33416dfb21 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e55aea01-80e6-60ae-e053-2995a90a9ca2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7545c79a-93ea-4f73-beb5-cac46b2ed7e9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd169dd8-70a0-b6b4-e053-6394a90a3a6f (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a3cf917-3569-4fc1-8b81-ffecfd2de005 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00f0fbda-eb62-4f79-ae9c-286b31eca733 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:208dbac2-2634-4aff-8e2c-e5ecb47145e2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5db0e3ff-fefb-4c54-b9f9-b555e482e147 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57536bd9-7dfa-4be5-854a-95fea43d54bc (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon tablets is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4239d09-2cb3-4e7d-b035-995ddcf386df (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c52e03-4c2e-4774-9397-f1f0ee99b320 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c25cf94-f30e-4940-9f8b-3cb34258ba04 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af1db3bf-1c7c-441e-8497-7c35f45fb00e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86296f99-efef-4cbb-84cb-097b2edcfe9c (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de82310-70e8-47b9-b1fc-6c6848b99455 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bccc4f11-6081-49a1-9abd-2f4c2d69b380 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 hours to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89dae05-6c39-4072-b8ee-c4c35b46f7d4 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b9b6076-180e-428b-b50a-5ab68ff65919 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1706aa1-9332-4faf-8d0c-88edd00b15e3 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5245f9ee-b4ca-24b6-e063-6394a90a0b1b (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Absorption Ramelteon is absorbed rapidly, with median peak concentrations occurring at approximately 0.75 hour (range, 0.5 to 1.5 hours) after fasted oral administration.
Projected row 1298
- Medicine slug
- ramelteon
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 40
- Source count
- 40
- Agreement rate
- 1
- Recorded readings
73.6 L
- Numeric value
- 73.6
- Unit
- L
- Source records
- 40
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 40 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2fc3b7-4600-c14e-e053-6394a90a2586 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7ca849d3-f0ba-45b5-9aec-f4b7ea105fac (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fc0db5-c68f-5af9-e053-2a95a90a5110 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57b24572-f601-b092-e063-6394a90afa53 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d22e6ae-2373-4a2f-8dda-d223230c6010 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1b48a-05c0-4058-8ccd-1971098b8ce1 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:094d5aa0-aa29-4898-928a-fe0d283a5271 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed37ac7c-ab7e-57b3-e053-2995a90a5b90 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b336438f-7951-d3b7-e053-2995a90a4d69 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c14d79c-ece1-40c7-b725-eeb85d6f347a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44be28b2-f079-40ce-b86d-8b60eda1a7c0 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:782503c6-a82f-4933-aa04-399123e9f5a9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15c8612-4065-4078-bff9-f2ffc1319654 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56d1ac8d-5131-4eed-e063-6294a90a402e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0a57843-81cb-474d-8e90-e04bbe93216a (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d6ad234-69ae-4e33-824d-cff5d1500a86 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c1ba52a-8e7a-844a-6c48-d1c9bf9fff0e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0cc378-4bc5-425c-8f41-43eb734c24d9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01dfc4c5-07d1-4dd7-a9ca-a94203b2e16d (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:229403c5-de9c-dc61-e063-6394a90a2a70 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8213998f-9a14-4ebb-a87a-4f33416dfb21 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e55aea01-80e6-60ae-e053-2995a90a9ca2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7545c79a-93ea-4f73-beb5-cac46b2ed7e9 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd169dd8-70a0-b6b4-e053-6394a90a3a6f (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a3cf917-3569-4fc1-8b81-ffecfd2de005 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00f0fbda-eb62-4f79-ae9c-286b31eca733 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:208dbac2-2634-4aff-8e2c-e5ecb47145e2 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5db0e3ff-fefb-4c54-b9f9-b555e482e147 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57536bd9-7dfa-4be5-854a-95fea43d54bc (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4239d09-2cb3-4e7d-b035-995ddcf386df (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32c52e03-4c2e-4774-9397-f1f0ee99b320 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c25cf94-f30e-4940-9f8b-3cb34258ba04 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af1db3bf-1c7c-441e-8497-7c35f45fb00e (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:86296f99-efef-4cbb-84cb-097b2edcfe9c (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9de82310-70e8-47b9-b1fc-6c6848b99455 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bccc4f11-6081-49a1-9abd-2f4c2d69b380 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a89dae05-6c39-4072-b8ee-c4c35b46f7d4 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b9b6076-180e-428b-b50a-5ab68ff65919 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1706aa1-9332-4faf-8d0c-88edd00b15e3 (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5245f9ee-b4ca-24b6-e063-6394a90a0b1b (opens source in a new tab)
Ramelteon label
Version not recorded · Effective date not recorded
Ramelteon has a mean volume of distribution after intravenous administration of 73.6 L, suggesting substantial tissue distribution.
Projected row 1299
- Medicine slug
- ramipril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 38
- Source count
- 36
- Agreement rate
- 1
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 36
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 36 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62f6aa5a-7587-4349-b61d-b2c235749979 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6187971a-2756-4791-8801-211bec0a6718 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7e61b5b-fb5b-ba15-e053-6394a90adc3c (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8d9a115-71a7-4580-abbd-865e98b5d3f6 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8cdec12-81d1-4ef4-82c0-d05d93c37a07 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7e49f05-6d4f-465a-b0d7-f704466a2e52 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3786664-a1b5-4914-99d6-79fb0e330e98 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01da05d8-e72e-4208-bf92-a5cd929f15ab (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd766bc-2a42-40b5-b33f-1a8b5ce2622e (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d270b634-0d6d-4614-b223-a2af1e238c2f (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef05b44e-4bf7-4afa-a5f6-06efa0d0abc3 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb23b7d-ed2b-4984-89c8-d0a509b917e1 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33bdfe96-1b7a-4859-b1c9-ef94b8bb7a2a (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1576188e-efd4-4e14-870e-fd9bd2751c45 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd3162eb-5f09-47ac-9efd-3ddeee695a25 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:543914e5-c164-4fc7-8007-9fab2b13dda7 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab3124b7-deed-8e04-e053-2a95a90a3b85 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab09a67e-18fe-c860-e053-2a95a90a4d03 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab324cb3-2aaa-b57f-e053-2995a90a2055 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:394a49a8-81bb-43ba-8d6a-fa6fa5030587 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:245d3580-77c6-4c0f-b324-c8514b792c59 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3513b8b-2d8a-456d-b942-a25ec1965b04 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f325b8-f33d-3b93-e053-2995a90aa660 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8be00433-3113-437e-8ab6-721af4d79185 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3806abdc-6aec-4252-bd79-e2c115b849aa (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd2d586-6851-4a40-e063-6394a90a0cab (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c58fb5-b415-4567-9790-55631705c5cd (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:055bb582-67cd-425a-8823-d543c14305ce (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45707435-4fc8-457e-9ff2-02d7be9b4a6e (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b87655-93c3-16a5-e053-2a95a90a593c (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb0892da-3db7-3202-e053-6394a90ab605 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6d57158-e8f9-4c91-8317-0374e0c87d33 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d856fb57-f1a0-49e6-bb2d-b4924af48515 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a91b706-c614-4472-92f2-4da5d7bdbf27 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf42121-8e85-4eae-82b4-bc029653b462 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c86139-b1f7-4e84-944f-94af883ce4ea (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The initial rapid decline, which represents distribution of the drug into a large peripheral compartment and subsequent binding to both plasma and tissue ACE, has a half-life of 2 to 4 hours.
Projected row 1300
- Medicine slug
- ramipril
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 38
- Source count
- 38
- Agreement rate
- 1
- Recorded readings
73%
- Numeric value
- 73
- Unit
- %
- Source records
- 38
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 38 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62f6aa5a-7587-4349-b61d-b2c235749979 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro , these percentages are independent of concentration over the range of 0.01 μg/mL to 10 μg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6187971a-2756-4791-8801-211bec0a6718 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7e61b5b-fb5b-ba15-e053-6394a90adc3c (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8d9a115-71a7-4580-abbd-865e98b5d3f6 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a8cdec12-81d1-4ef4-82c0-d05d93c37a07 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e1dfacf-b831-4743-a874-9a5e5ef8a120 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro , these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7e49f05-6d4f-465a-b0d7-f704466a2e52 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro , these percentages are independent of concentration over the range of 0.01 µg/mL to 10 µg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3786664-a1b5-4914-99d6-79fb0e330e98 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01da05d8-e72e-4208-bf92-a5cd929f15ab (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 μg/mL to10 μg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afd766bc-2a42-40b5-b33f-1a8b5ce2622e (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d270b634-0d6d-4614-b223-a2af1e238c2f (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ef05b44e-4bf7-4afa-a5f6-06efa0d0abc3 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7e9e84f7-ff47-463d-bf47-7a9745960aae (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro , these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5fb23b7d-ed2b-4984-89c8-d0a509b917e1 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33bdfe96-1b7a-4859-b1c9-ef94b8bb7a2a (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1576188e-efd4-4e14-870e-fd9bd2751c45 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd3162eb-5f09-47ac-9efd-3ddeee695a25 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:543914e5-c164-4fc7-8007-9fab2b13dda7 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab3124b7-deed-8e04-e053-2a95a90a3b85 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab09a67e-18fe-c860-e053-2a95a90a4d03 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab324cb3-2aaa-b57f-e053-2995a90a2055 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:394a49a8-81bb-43ba-8d6a-fa6fa5030587 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:245d3580-77c6-4c0f-b324-c8514b792c59 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3513b8b-2d8a-456d-b942-a25ec1965b04 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2f325b8-f33d-3b93-e053-2995a90aa660 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8be00433-3113-437e-8ab6-721af4d79185 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3806abdc-6aec-4252-bd79-e2c115b849aa (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bd2d586-6851-4a40-e063-6394a90a0cab (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5c58fb5-b415-4567-9790-55631705c5cd (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:055bb582-67cd-425a-8823-d543c14305ce (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro , these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45707435-4fc8-457e-9ff2-02d7be9b4a6e (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b87655-93c3-16a5-e053-2a95a90a593c (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb0892da-3db7-3202-e053-6394a90ab605 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6d57158-e8f9-4c91-8317-0374e0c87d33 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d856fb57-f1a0-49e6-bb2d-b4924af48515 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a91b706-c614-4472-92f2-4da5d7bdbf27 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcf42121-8e85-4eae-82b4-bc029653b462 (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6c86139-b1f7-4e84-944f-94af883ce4ea (opens source in a new tab)
Ramipril label
Version not recorded · Effective date not recorded
The serum protein binding of ramipril is about 73% and that of ramiprilat about 56%; in vitro, these percentages are independent of concentration over the range of 0.01 mcg/mL to 10 mcg/mL.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1290Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.